BiomX is a Ness Ziona, Israel–based microbiome drug discovery company led by CEO Jonathan Solomon. It develops customized phage therapies that target and destroy harmful bacteria implicated in chronic diseases such as inflammatory bowel disease (IBD) and cancer. The company discovers and validates proprietary bacterial targets and then customizes natural and engineered phage compositions against those targets. BiomX's lead programs include candidates for the treatment of acne and IBD. The company recently closed a $32M Series B equity financing to advance its pipeline. Proceeds from the financing will be used primarily to advance its leading drug candidates for acne and IBD into the clinic. BiomX is an Israel-based company developing drugs using microbiome bacteria. The firm focuses on creating therapeutics derived from or based on microbiome bacteria to treat disease. It recently raised $24 million in an early-stage funding round. The company said the funds will be used to advance its therapeutic pipeline toward clinical stages. Investors in the financing include OrbiMed, Johnson & Johnson Innovation, Takeda Ventures, Seventure Partners, MiraeAsset, the SBI Japan-Israel Innovation Fund and other European investors. No operational metrics or valuation were disclosed in the article.

Total raised

$56M

Funding rounds

2

Latest round

Series B

Latest activity

Feb 2019